OWC Pharmaceutical Research Corp. - Consolidated Statements of Operations	3 Months Ended		6 Months Ended
	Jun. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) $ / shares shares	Jun. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) $ / shares shares
Consolidated Statements of Operations
Revenues	$ 0	$ 0	$ 0	$ 0
Expenses:
General and administrative expenses	84,467	532,815	306,023	824,090
Research and development	34,776	76,612	71,819	189,940
Loss from operations	(119,243)	(609,427)	(377,842)	(1,014,030)
Other income (expenses):
Interest expense	$ (40,562)	$ 0	$ (41,560)	$ 0
Change in fair value of derivative liabilities	16,647	0	(11,598)	0
Amortization of debt discount			$ 57,119	$ 0
Total other income (expense)	(54,488)	0	(110,277)	0
Total costs and expenses	$ (173,731)	$ (609,427)	$ (488,119)	$ (1,014,030)
Loss loss before income taxes	$ (173,731)	$ (609,427)	$ (488,119)	$ (1,014,030)
Income tax	0	0	0	0
Net loss			$ (488,118)	$ (1,014,030)
Basic and diluted per share amounts:
Basic and diluted net loss | $ / shares	$ (0.00)	$ (0.02)	$ (0.01)	$ (0.02)
Weighted average shares outstanding (basic and diluted) | shares	81,460,875	40,129,063	81,460,875	58,799,819